Photo detail

Lumena CEO, Mike Grey, says the recent $23 million in Series A financing will fund the clinical development of LUM001, its lead product candidate for the treatment of a disorder called cholestatic liver disease.

Stories this photo appears in:

Lumena Secures $23M to Advance Trials for Liver Disease Drug

BIOTECH: PwC Reports Q1 2013 Drop In Dollars and Deals

Lumena Pharmaceuticals Inc., a San Diego-based manufacturer of liver disease drugs, recently secured $23 million in Series A financing.

Tease photo